<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352742</url>
  </required_header>
  <id_info>
    <org_study_id>ATN-224-007</org_study_id>
    <nct_id>NCT00352742</nct_id>
  </id_info>
  <brief_title>A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma</brief_title>
  <official_title>A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Attenuon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Attenuon</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the safety and effect of ATN-224 in combination with&#xD;
      bortezomib (Velcade®) in patients with Multiple Myeloma who are relapsed from or refractory&#xD;
      to bortezomib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma is a bone marrow based malignancy of plasma cells that is highly treatable&#xD;
      but rarely curable. Angiogenesis, defined as the growth of new blood vessels from&#xD;
      pre-existing vessels, is a requirement for the growth of nearly all tumors. An increase in&#xD;
      bone marrow angiogenesis is present in Multiple Myeloma and correlates with disease&#xD;
      progression. Several new therapies that target angiogenic pathways have shown clinical&#xD;
      efficacy. ATN-224 is a small molecule that has been shown in pre-clinical studies to be&#xD;
      antiangiogenic.&#xD;
&#xD;
      Using one agent to overcome resistance of another agent is a treatment regimen used in&#xD;
      oncology. A preclinical study with the combination of ATN-224 and bortezomib shows that the&#xD;
      combination is more effective than either single agent in a bortezomib resistant cell line.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study</measure>
    <time_frame>Ongoing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Efficacy</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Preliminary evidence of efficacy</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: progression-free survival and duration of response</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATN-224 + bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATN-224 + bortezomib</intervention_name>
    <description>ATN-224 and bortezomib dose to be determined in Phase I portion of study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed multiple myeloma that has been treated with&#xD;
             at least one different prior anti-myeloma regimens including one with bortezomib and&#xD;
             is currently showing evidence of progressive disease&#xD;
&#xD;
          2. Myeloma that is refractory to the most recent bortezomib-containing regimen as&#xD;
             demonstrated by progressive disease while on bortezomib or that relapsed within 12&#xD;
             weeks of the last dose of bortezomib either as a single agent or in combination with&#xD;
             other agents&#xD;
&#xD;
          3. Measurable disease defined as a serum M-protein concentration on electrophoresis ≥1&#xD;
             g/dL of IgG myeloma or ≥0.5 g/dL of IgA myeloma or IgM myeloma or urinary excretion of&#xD;
             monoclonal light chain ≥200 mg/24 hours&#xD;
&#xD;
          4. Age &gt;18 years&#xD;
&#xD;
          5. Life expectancy of greater than 3 months&#xD;
&#xD;
          6. ECOG performance status &lt;2 (Karnofsky &gt;60%; see Appendix A)&#xD;
&#xD;
          7. Adequate organ and marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count ≥1,000/uL&#xD;
&#xD;
               -  platelets ≥75,000/uL&#xD;
&#xD;
               -  hemoglobin ≥8 g/dL&#xD;
&#xD;
               -  total bilirubin ≤2 X institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  AST(SGOT) and ALT(SGPT) ≤3 X ULN&#xD;
&#xD;
               -  creatinine clearance ≥30 mL/min (measured or calculated)&#xD;
&#xD;
             Patients are allowed to receive blood transfusions before receiving their first dose&#xD;
             of ATN-224 to bring the hemoglobin level to ≥8 g/dL to meet eligibility criteria.&#xD;
&#xD;
          8. Use of adequate contraception. The effects of ATN 224 on the developing human fetus at&#xD;
             the recommended therapeutic dose are unknown. For this reason and because&#xD;
             antiangiogenic agents are known to be teratogenic, women of child-bearing potential&#xD;
             and men with partners of child-bearing potential must agree to use adequate&#xD;
             contraception (hormonal and/or barrier method of birth control; abstinence) prior to&#xD;
             study entry and for the duration of study participation through the follow up visit 28&#xD;
             days after the last dose of ATN 224.&#xD;
&#xD;
          9. Willingness to forego taking copper- or zinc-containing vitamins or supplements&#xD;
&#xD;
         10. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)&#xD;
             or thalidomide, lenalidomide, dexamethasone, arsenic trioxide, bortezomib, or&#xD;
             glucocorticosteroids within 3 weeks prior to the first dose of ATN-224 or failure to&#xD;
             recover from reversible adverse events due to agents administered previously&#xD;
&#xD;
          2. Patients who cannot tolerate, based on previous experience, the assigned dose of&#xD;
             bortezomib, including those with ≥ Grade 2 neuropathy&#xD;
&#xD;
          3. Concurrent administration of any other investigational agents&#xD;
&#xD;
          4. History of malabsorption syndromes or other gastrointestinal disorders that may affect&#xD;
             ATN-224 absorption, including bowel obstruction, celiac disease, sprue, cystic&#xD;
             fibrosis&#xD;
&#xD;
          5. Ineligible to receive omeprazole (Prilosec® OTC) or other long-acting antacid&#xD;
&#xD;
          6. Inability to swallow study medication capsules&#xD;
&#xD;
          7. Not a suitable candidate in the opinion of the investigator for additional bortezomib&#xD;
             therapy&#xD;
&#xD;
          8. Other serious medical or psychiatric illness preventing informed consent or intensive&#xD;
             treatment&#xD;
&#xD;
          9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
         10. Women who are pregnant or lactating&#xD;
&#xD;
         11. Known history of HIV&#xD;
&#xD;
         12. History of another prior cancer, except basal cell carcinoma or carcinoma in situ of&#xD;
             the cervix (or if there has been no evidence of recurrence for at least 5 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Gordon, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Hematolgy-Oncology Medical Group of Fresno, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Myeloma and Bone Cancer Research</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2006</study_first_posted>
  <last_update_submitted>October 27, 2008</last_update_submitted>
  <last_update_submitted_qc>October 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jennifer Callahan, Senior Manager, Clinical Development</name_title>
    <organization>Attenuon, LLC</organization>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>bortezomib</keyword>
  <keyword>ATN-224</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <keyword>antiangiogenic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Tetrathiomolybdate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

